1 Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States

2

3 Heather Kalish*¹, Carleen Klumpp-Thomas*², Sally Hunsberger*³, Holly Ann Baus⁴, Michael P Fay³, 4 Nalyn Siripong⁵, Jing Wang⁶, Jennifer Hicks¹, Jennifer Mehalko⁷, Jameson Travers², Matthew Drew⁷, Kyle 5 Pauly¹, Jacquelyn Spathies¹, Tran Ngo⁸, Kenneth M. Adusei⁸, Maria Karkanitsa⁸, Jennifer A Croker⁹, Yan Li¹⁰, Barry I. Graubard¹¹, Lindsay Czajkowski⁴, Olivia Belliveau¹², Cheryl Chairez¹², Kelly Snead⁷, Peter 6 7 Frank⁷, Anandakumar Shunmugavel⁸, Alison Han⁴, Luca T. Giurgea⁴, Luz Angela Rosas⁴, Rachel Bean⁴, Rani Athota⁴, Adriana Cervantes-Medina⁴, Monica Gouzoulis⁴, Brittany Heffelfinger⁴, Shannon Valenti⁵, 8 9 Rocco Caldararo¹³, Michelle M. Kolberg¹⁴, Andrew Kelly², Reid Simon², Saifullah Shafiq², Vanessa Wall⁷, 10 Susan Reed⁴, Eric W Ford⁹, Ravi Lokwani⁸, John-Paul Denson⁷, Simon Messing⁷, Sam G. Michael²,

- 11 William Gillette⁷, Robert P. Kimberly⁹, Steven E. Reis⁵, Matthew D. Hall², Dominic Esposito⁷, Matthew J.
- 12 Memoli^{4†}, Kaitlyn Sadtler^{8†}
- 13
- ¹Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of
- 15 Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20894
- 16 ²National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD
- 17 20850
- ¹⁸ ³Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes
- 19 of Health, Bethesda, MD 20894
- 20 ⁴Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious
- 21 Diseases, National Institutes of Health, Bethesda, MD 20894
- ⁵Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania
- ⁶Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research,
 Frederick MD 21702
- ⁷Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research,
 Frederick MD 21702
- 27 ⁸Section on Immuno-Engineering, National Institute of Biomedical Imaging and Bioengineering, National
- 28 Institutes of Health, Bethesda, MD 20894
- 29 ⁹Center for Clinical and Translational Science, School of Medicine, University of Alabama at
- 30 Birmingham, Birmingham, AL 35294
- 31 ¹⁰Joint Program in Survey Methodology, Department of Epidemiology and Biostatistics, University of
- 32 Maryland College Park, College Park, MD 20742
- 33 ¹¹Division of Cancer Epidemiology & Genetics, Biostatistics Branch, National Cancer Institute, National
- 34 Institutes of Health, Bethesda MD 20894
- ³⁵ ¹²Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National
- 36 Institutes of Health, Bethesda, MD 20894
- ¹³Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Leidos Biomedical
- 38 Research, Inc, Frederick MD 21702
- ¹⁴Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes
- 40 of Health, Bethesda, MD 20894
- 41
- 42 *these authors contributed equally
- 43 [†]Address correspondence to: Dr. Matthew Memoli (memolim@nih.gov) or Dr. Kaitlyn Sadtler
- 44 (<u>kaitlyn.sadtler@nih.gov</u>)

- 45 ABSTRACT
- 46

47 Asymptomatic SARS-CoV-2 infection and delayed implementation of diagnostics have led to poorly 48 defined viral prevalence rates. To address this, we analyzed seropositivity in US adults who have not 49 previously been diagnosed with COVID-19. Individuals with characteristics that reflect the US population 50 (n = 11,382) and who had not previously been diagnosed with COVID-19 were selected by quota sampling 51 from 241,424 volunteers (ClinicalTrials.gov NCT04334954). Enrolled participants provided medical, 52 geographic, demographic, and socioeconomic information and 9,028 blood samples. The majority (88.7%) 53 of samples were collected between May 10th and July 31st, 2020. Samples were analyzed via ELISA for anti-Spike and anti-RBD antibodies. Estimation of seroprevalence was performed by using a weighted 54 55 analysis to reflect the US population. We detected an undiagnosed seropositivity rate of 4.6% (95% CI: 2.6 56 -6.5%). There was distinct regional variability, with heightened seropositivity in locations of early 57 outbreaks. Subgroup analysis demonstrated that the highest estimated undiagnosed seropositivity within 58 groups was detected in younger participants (ages 18-45, 5.9%), females (5.5%), Black/African American 59 (14.2%), Hispanic (6.1%), and Urban residents (5.3%), and lower undiagnosed seropositivity in those with 60 chronic diseases. During the first wave of infection over the spring/summer of 2020 an estimate of 4.6% of 61 adults had a prior undiagnosed SARS-CoV-2 infection. These data indicate that there were 4.8 (95% CI: 62 2.8-6.8) undiagnosed cases for every diagnosed case of COVID-19 during this same time period in the 63 United States, and an estimated 16.8 million undiagnosed cases by mid-July 2020.

64 INTRODUCTION

65

66 COVID-19, the disease caused by SARS-CoV-2 infection, presents with a spectrum of illness ranging from 67 asymptomatic to severe disease and death. As with most respiratory viral diseases, it is difficult to estimate 68 the true prevalence of the disease during a pandemic and the extent of its spread is only known after 69 extensive study¹⁻³. The majority of patients infected develop robust antibody responses against the viral 70 spike (S), nucleocapsid (N), and envelope (E) proteins that can be detected via serologic testing⁴⁻⁸. Anti-S antibodies persist for months, and can neutralize infection⁹. Frequently, these neutralizing antibodies bind 71 72 the receptor binding domain (RBD) of the spike protein, but antibodies against the spike S2 domain have also been observed¹⁰⁻¹⁵. 73

74

75 To characterize the spread of SARS-CoV-2 infection in the United States, we evaluated seropositivity in a 76 national survey of participants who had not previously been diagnosed with SARS-CoV-2 infection. We 77 used quota sampling from a large pool of volunteers to obtain a representative sample and performed 78 statistical weighting to generate prevalence estimates which provide a clear picture of the extent of SARS-79 CoV-2 infection. To ensure accurate classification of seropositivity, we utilized our dual-antigen ELISA 80 protocol that evaluated IgG and IgM antibodies against both the full spike ectodomain and the RBD^{7,16}. 81 These foundational considerations generated critical data needed to estimate spread during the pandemic 82 and gain insight into the potential future outcomes.

83

These results, including the subgroup analysis, give us a previously undescribed view into the spread of the pandemic by more clearly identifying the large numbers of individuals with undiagnosed infections during the initial months of the pandemic. These data are of great importance as we consider the impact vaccination may have on the future course of the pandemic and plan for current and future available vaccines to be administered. In addition, these data can also help us better assess the public health measures taken during the pandemic and how to take the best approaches forward to any future public health emergencies. 90 METHODS

91

92 *Study Protocol:*

93

94 This study was designed to determine the seroprevalence of anti-SARS-CoV-2 antibodies in adults 18 years 95 of age or older in the United States who had not been previously diagnosed with COVID-19. The primary 96 endpoint was the weighted estimate of seroprevalence in the US. Secondary endpoints were weighted 97 estimates for subgroups categorized by demographics/risk factors. An initial period enrolled a convenience 98 sample of 593 volunteers prior to the quota sample. Participants across the US (all 50 states and DC) were 99 then enrolled via telephone consent from a pool of volunteers who provided basic demographic data in 100 response to the study announcement. Recruitment calls were made from three sites: NIAID Laboratory of 101 Infectious Diseases Clinical Studies Unit, the University of Pittsburgh CTSI, and the University of Alabama 102 at Birmingham CCTS. Selection of participants is described below. Selected participants were contacted 103 by the study team, consented, and sent a blood microsampling kit and online questionnaire in REDCap 104 (project-redcap.org). For a small subset of participants (n = 214) working on the NIH campus, serum was 105 collected via venipuncture. This study (ClinicalTrials.gov NCT04334954) was approved by the National 106 Institutes of Health Institutional Review Board and conducted in accordance with the provisions of the 107 Declaration of Helsinki and Good Clinical Practice guidelines. All participants provided verbal informed 108 consent prior to enrollment.

109

110 Participant Selection

111

112 All volunteers were emailed an initial survey to collect basic demographic characteristics. Survey responses 113 were de-identified and aggregated by sub-category of state, type of locality approximated from zip codes, 114 age, sex, race, and ethnicity (Figure 1). Target sample sizes for these sub-categories were determined from 115 the U.S. census, and were updated every evening based on the characteristics of people who had already 116 enrolled to assure that individuals in each sub-category were enrolled evenly over time. Within each sub-117 category, participants were initially assigned a selection probability calculated from the target number as a 118 proportion of the available pool. Specific sub-categories that had insufficient numbers were aggregated to 119 estimate their impact on the overall distribution of the 6 main characteristics. If a particular characteristic 120 had insufficient numbers, sample probabilities were boosted for volunteers who had the characteristic. For 121 each day's call list, the most representative of 20,000 randomly generated lists was used, each list drawn 122 without replacement from the volunteer pool based on the sampling probabilities previously defined. 123 Representativeness was assessed by estimating a weighted sum of squared differences from the desired 124 targets and picking the list with the lowest deviation. Unselected participants were eligible to be called at a

125 later date. This algorithm is designed such that each cohort of invited participants is representative of the

diversity of the US population with respect to the 6 sampling variables (see Statistical Supplement Section3.4).

128

129 Sample Collection:

130

131 Participants provided blood samples by mail using a Mitra microsampling kit (Neoteryx, Torrance, CA) or 132 standard venipuncture. Microsampling kits contained visual instructions on the sampling process, bandages, 133 gauze, lancets, and four 20 µl microsampling devices for a total collection of 80 µl of whole blood. 134 Participants utilized the lancet to draw blood from their fingertip and collect blood onto each of the four 135 microsamplers. Participants returned the dried microsamplers with desiccant via overnight shipping. Those 136 who underwent venipuncture did so in the NIH Clinical Center phlebotomy lab where 18 ml of blood was 137 collected in a serum separator and whole blood tube. Once received in the laboratory serum samples were 138 processed, and microsamplers were stored dry at -80°C until elution and analysis.

139

140 Serologic Assays:

141

142 Antibodies from samples were analyzed using ELISA as previously described^{7,16-18}. In order to maintain 143 longitudinal quality control and ensure that the assays remained stable across multiple months of assay 144 implementation, positive and negative controls were included on each assay plate and monitored for 145 stability (Supplemental Fig. 1). Seropositivity cut points were defined by evaluating 300 true negative 146 samples and 56 true positive samples. Positivity thresholds were based on the mean optical density 147 (absorbance) plus 3 standard deviations (see Supplemental Materials for details). The final criterion of a 148 Spike⁺ and RBD⁺ for any combination of IgG or IgM gave estimated sensitivity and specificity of 1, with 149 raw values for recombinant antibody results reported in **Supplemental Fig. 2** and **Supplemental Table 1**. 150 Additionally, IgA was evaluated via previously described ELISA to further phenotype the participant's

151 serologic status.

152

154

155 The previously described iterative quota sampling continuously matched the proportion of people in the

156 study with the census estimated proportion of people in the country on 6 variables (**Table 1, Figure 1**).

157 This ensured that each periodic sample of participants over the course of the study were representative, and

¹⁵³ Statistical Analysis

158 the time effects of the pandemic were approximately independent of those 6 variables. Each participant was 159 asked demographic and health-related questions that matched ones on the Behavioral Risk Factor Surveillance System (BRFSS) survey, a large probability-based national survey¹⁹. Responses to those 160 161 matching questions were used with BRFSS survey data to adjust estimators to account for important criteria 162 that may be related to both selection probability and seropositivity but were not accounted for in the quota 163 sampling. Those adjusted estimators used weighting based on the propensity of being a quota sample versus 164 a BRFSS sample participant and poststratification to US census data. It additionally accounted for 165 sensitivity and specificity. Confidence intervals were calculated for the final seroprevalence estimates 166 accounting for both the variability of the weighting and of the sensitivity and specificity adjustment. The 167 ratio of undiagnosed cases over diagnosed cases was estimated as the final seroprevalence estimate times a 168 factor calculated from the daily national population and diagnosed cases. For more methods and details see 169 Section 3 of the Supplementary Materials.

170

171 **RESULTS**

172

173 Enrollment and Demographic Representation

174

175 Recruitment took place from April 1, 2020 until August 4, 2020. During that time 11,283 participants were 176 enrolled from a pool of 241,424 volunteers. Of these participants, 214 had blood collected via venipuncture 177 and 11,069 were sent microsamplers. Over 80% of the microsamplers were returned (9,089 participants). 178 Ultimately 9,028 participant samples were analyzed via ELISA for presence of SARS-CoV-2 antibodies. 179 Of those, 8,058 participants had complete clinical questionnaire data and were included in the weighted 180 analysis (Figure 1). The majority (>88%) of sample collection occurred within the 11-week period between May 10th to July 31st, 2020 (**Supplemental Fig. 3**). The six major demographic factors used in participant 181 182 selection are summarized in Table 1. Participant sampling was highly representative of the U.S. population. 183 When expanded to include the additional 10 demographic or health related factors captured by the BRFSS, 184 many factors were well matched, but there were some differences: our sample population was more highly 185 educated, employed, and had better access to healthcare (Table 1). 186

187 Estimates of Seroprevalence

188

189 There were 304 seropositive participants in the analysis set (Figure 2a,b). This gave a weighted estimate

- 190 of 4.6% of the undiagnosed adults in the U.S. population that were seropositive for SARS-CoV-2 (95% CI:
- 191 2.6% to 6.5%, n = 8058 complete testing and survey). Using this average rate over the study period, we

estimate that there were 4.8 undiagnosed cases per each diagnosed case over the course of the study (95%

- 193 CI: 2.8, 6.8). In seropositive participants, 36.51% were IgG⁺IgM⁺IgA⁺, 28.29 % were IgG⁺IgM⁻IgA⁺,
- 194 17.11% were $IgG^{+}IgM^{-}IgA^{-}$, 13.16% were $IgG^{+}IgM^{+}IgA^{-}$, 4.28% were $IgG^{-}IgM^{+}IgA^{-}$, and 0.66% were
- 195 IgG⁻IgM⁺IgA⁺ (Figure 2a-c, Supplemental Fig. 4).
- 196

197 We found regional variations of seroprevalence estimates across the US (Fig. 2d, 3). The Northeast and 198 Mid-Atlantic Regions showed the highest rates of seropositivity whereas the lowest in the Midwest. Urban 199 areas were estimated to have higher levels of seropositivity (5.3%) compared to rural areas (1.1%) 200 seropositivity) at the time samples were collected. Estimates of seroprevalence were calculated for other 201 demographic subgroups (Figure 3). The youngest age group, 18-44, had the highest estimated 202 seropositivity (5.9%). Estimated seroprevalence for females was 5.5% and 3.5% in males. The 203 seroprevalence estimate for Black/African Americans was highest at 14.2% followed by participants who 204 self-identified as other/unlisted race (11.1%), American Indian/Alaska Native (6.8%), followed by 205 White/Caucasian (2.5%), while those identifying as Asian displayed the lowest seroprevalence estimate 206 (2.0%).

207

208 Participants who reported a known exposure to a SARS-CoV-2-infected individual had a higher 209 seroprevalence estimate (15.6%) compared to those who did not (2.7%). In comparison to the national 210 average (4.6%), those that worked from home had a lower seropositivity estimate of 3.0%. Those who 211 reported prior vaccination (influenza 3.2% and/or pneumonia 2.3%) had a lower likelihood for undiagnosed 212 seropositivity. Those who had health conditions associated with poor outcomes in SARS-CoV-2 infection, 213 including coronary heart disease, asthma, and diabetes, displayed lower rates of seropositivity (Figure 4). 214 Other health conditions were also correlated with a decreased seropositivity rate such as skin cancer, stroke, 215 or arthritis.

216

217 **DISCUSSION**

218

This study demonstrates that spread of the SARS-CoV-2 virus in the US during the first six months of the pandemic was more widespread than has been suggested by data reporting diagnostic test-confirmed cases. Similar to responses to other respiratory viruses, such as influenza, many individuals develop asymptomatic or mild disease that is not medically attended and therefore never diagnosed. Our findings indicate that there are nearly five individuals with a previous asymptomatic infection for every diagnosed case. Furthermore, patterns of our seroprevalence data match well with those of diagnosed cases reported during a similar timeframe.²⁰ For example, the greater seropositivity estimated in densely populated urban areas follows the observed initial spread of SARS-CoV-2. In comparison to the national average, we found that the Midwest, South, and West had lower seroprevalences during the study timeframe, which preceded a substantial increase in infections in these regions detected by viral testing.

229

230 Our data suggest that the youngest age group had the highest undiagnosed seroprevalence, which is 231 consistent with observations that they display less severe symptoms than older patients²¹. We also found 232 higher undiagnosed seroprevalence in females, possibly suggesting a higher risk for asymptomatic disease. 233 Participants with chronic diseases that are more likely to be associated with severe clinical manifestations 234 of COVID-19, including diabetes, heart disease, and asthma, had a lower prevalence of asymptomatic 235 SARS-CoV-2 infection in comparison to the national average. Those with known exposure to SARS-CoV-236 2 infected individuals had a higher estimated incidence of undiagnosed seropositivity. We also found that 237 Black, African American, and Hispanic participants had higher undiagnosed seropositivity, correlating with 238 national data on disease burden in these sub-groups.

239

This study is the first to report a representative sample across the US and to evaluate regional, demographic and socioeconomic differences in the prevalence of asymptomatic SARS-CoV-2 infection. In contrast, other reports of seroprevalence data focus on a specific group of individuals or geographic location²². Our results provide new insight into the spread of SARS-CoV-2. Our estimate of the national undiagnosed exposure rate provides information on the scope of infection during the first six months of the pandemic. This work extends findings from smaller foundational studies of limited populations²³⁻³⁷ by generating an accurate estimate of nationwide and subgroup prevalence.

247

248 Our results estimate that there are approximately 4.8 undiagnosed cases (95% CI 2.76-6.81) for every 249 identified case of COVID-19, suggesting a potential 16.8 million undiagnosed cases by mid-July 2020 in 250 addition to the reported 3 million diagnosed cases in the United States. These data suggest a higher level of 251 infection-induced immunity exists in the population and the size of those with this immunity is even greater 252 now as the virus continued to spread in the months since this study was performed. Further long-term 253 studies of immunity in the population will be necessary to further understand durability of response to the 254 vaccine versus infection, how infection-induced immunity impacts vaccine response and performance, and 255 if herd immunity can play a role in controlling SARS-CoV-2 spread. In addition, further subgroup analysis 256 of our data will be useful in clarifying the spread of disease in the presence of public health measures and 257 how we may be able to refine and further target those measures in the future. 258

259

260 Limitations

261

262 Although we were able to recruit a cohort with demographics representative of the general US population, 263 our study has several limitations. First, although extensive statistical adjustments were made, our study 264 cohort is based on a non-random volunteer sample which can have selection bias. However, many 265 traditional random sampling studies using probability sampling design have very low response rates, calling into question the advantages of that practice^{38,39}. Our study population also exhibited some differences from 266 267 the general US population, such as higher education level and access to healthcare that had to be adjusted 268 for with statistical weighting. We utilized both census and behavioral data to weight our results though it is 269 possible that there are variables associated with disease transmission that are not accounted for in our 270 weighting.

271

272 CONCLUSIONS

273

These data suggest a much larger spread of the COVD-19 pandemic than originally thought and have implications in basic understanding of SARS-CoV-2 spread, epidemiologic characteristics of its spread and prevalence in different communities, and potential impact on decisions involved in vaccine rollout. Continued large-scale surveillance of SARS-CoV-2 immunity is in progress, discriminating infection-based and vaccine-induced antibody responses, and mathematical models will be generated to understand the pandemic, vaccine performance, public health measure efficacy, and providing insight for our approach to handling the next virus with pandemic potential.

281 ACKNOWLEDGEMENTS

282

283 Firstly, we would like to thank the participants in this study, without whom it would not have been possible. 284 The authors would like to acknowledge Dr. Corbett and Dr. Graham of the NIAID VRC for their generous 285 donation of coronavirus spike expression plasmid, and Dr. Aaron Schmidt, J Feldman, BM Hauser and T 286 M Caradonna of the Ragon Institute of MGH, MIT, and Harvard for their donation of their RBD expression 287 plasmid. We thank John Crissey and the CRIMSON team (NIAID, NIH) for their assistance and 288 contributions to the study and data management. We thank Dr. Jason McLellan for scholarly discussions 289 regarding the spike S-2P construct. We thank the CCTS Clinical Research Support Program (A. Delbridge, 290 L. Dukes), UAB School of Public Health and its Survey Research Unit (L. Battle, J. Carson, M. DeRamus, 291 T. Fields, T. Graham, T. Jackson, E. Pruitt, A. Underwood, P. Wolff), the University of Pittsburgh Clinical 292 and Translational Science Institute staff and leadership (J. Avolio, L. Bash, S. Clayton, M. Cristinziano, K. 293 Daw, C. Fascetti, E. Gyurisin, J. Huwe, N. Jones, D. Mathias, S. Mathias, A. Mykita, B. Petersen, M. 294 Phillips, C. Rush, E. Shepherd, S. Shetty, A. Socci, L. Stearns, S. Ugbomah, K. Underwood, L. Yasko) and 295 University of Pittsburgh Information Technology (D. McGaughey, S. Ritzman, T. Smith) for their 296 contributions to this work. We would like to thank Mr. Denzel Bernard for his assistance with sample 297 delivery, and Dr. Stephanie Ford-Scheimer for organizational assistance. This research was supported in 298 part by the Intramural Research Program of the NIH, including the National Institute for Biomedical 299 Imaging and Bioengineering, the National Institute of Allergy and Infectious Disease, and the National 300 Center for Advancing Translational Sciences. This project has been funded in part with Federal funds from 301 the National Cancer Institute, National Institutes of Health, under contract number HHSN261200800001E, 302 75N91019D00024, Task Order No. 75N91019F00130, Clinical and Translational Science Awards Program 303 grants UL1TR003096 (UAB) and UL1TR001857 (University of Pittsburgh). The content of this publication 304 does not necessarily reflect the views or policies of the Department of Health and Human Services, nor 305 does mention of trade names, commercial products, or organizations imply endorsement by the U.S. 306 Government. Disclaimer: The NIH, its officers, and employees do not recommend or endorse any company, 307 product, or service.

308 TABLES & LEGENDS

	US Population (BRFSS)			CoV2 Serosurvey Population		
			weighted			
	n	%	(%)	n	%	
Selection Criteria						
Region						
North East	91307	21.19	17.6	1508	16.7	
Midwest	67110	15.57	16.97	1445	16.01	
Mid-Atlantic	80979	18.79	16.91	1833	20.3	
South/Central	60482	14.03	15.35	1293	14.32	
Mountain/Southwest	86204	20	15.89	1392	15.42	
West/Pacific	44866	10.41	17.27	1557	17.25	
Age Group						
18 - 45	125081	28.59	46	3837	42.51	
45 - 70	207749	47.49	39.84	3783	41.91	
70 - 95	104605	23.91	14.17	1407	15.59	
Sex						
Male	197411	45.24	48.66	4318	47.83	
Female	238911	54.76	51.34	4710	52.17	
Urban/Rural						
Urban	365714	84.9	93.48	8550	94.78	
Rural	65234	15.1	6.52	471	5.22	
Race						
White only	345710	81	73.41	6986	77.4	
Black only	37862	8.87	12.9	830	9.2	
Others	43219	10.13	13.69	1210	13.41	
Ethnicity						
Hispanic	36941	8.53	17.06	1495	16.56	
Not Hispanic	395931	91.47	82.94	7532	83.44	
Additional Weighting Criteria						
Children						
Yes	113408	26.21	35.81	2943	32.88	
No	319281	73.79	64.19	6009	67.12	
Education						
<=HS	151606	34.79	41.07	240	2.68	
College	119979	27.53	30.88	1284	14.35	
>=College	164229	37.68	28.05	7422	82.96	
Homeowner						
Own	305545	70.36	66.49	6635	74.12	

Rent	107208	24.69	27.32	1861	20.79
Others	21535	4.96	6.19	456	5.09
Employment					
Employed	219493	50.75	57.74	6364	71.09
NLF	174920	40.45	31.38	2129	23.78
Unemployed	38053	8.8	10.88	459	5.13
Health Insurance					
Yes	400028	91.86	87.85	8697	97.31
No	35433	8.14	12.15	240	2.69
Flu Vaccinated				• •	
Yes	234727	59	50.62	6198	73.73
No	163124	41	49.38	2208	26.27
Cardiovascular Disease					
Yes	52284	12.07	9.07	354	3.98
No	380985	87.93	90.93	8541	96.02
Pulmonary Disease					
Yes	84102	19.33	18.53	1671	18.96
No	350913	80.67	81.47	7140	81.04
Immune Disease					
Yes	170115	39.14	29.29	2039	23.1
No	264571	60.86	70.71	6787	76.9
Diabetes					
Yes	60703	13.9	11.41	482	5.41
No	375876	86.09	88.59	8430	94.59

309 Table 1: Characteristics of serosurvey population in comparison to United States population. Census

310 and Behavioral Risk Factor Surveillance System (BRFSS, 2018) data on selection criteria were utilized for

311 quota-based sampling. Other values from BRFSS were utilized for statistical weighting. The comparisons

312 between the estimated proportions in the United States (BRFSS) versus our sample population for the

313 SARS-CoV-2 serosurvey are displayed in this table.

314 FIGURES AND LEGENDS



315

316

Figure 1: Serosurvey overview and statistical workflow. A flow chart of donor recruitment through data analysis displaying steps in data acquisition and any attrition from data sets if applicable. Key: Ovals = starts and ends, gray rectangles = subsets of participants in this study, blue parallelograms = individuals from outside data sets that contribute to adjusted prevalence estimates, blue rounded rectangles = analysis processes.







333

	Pos No.	Total No.		Estimate	95% CI
Overall	304	8058	(•••)	0.046	(0.026, 0.065)
Region					
NorthEast	95	1345	()	0.075	(0.039, 0.124)
Mid-West	43	1276	(•)	0.016	(0.003, 0.024)
Mid-Atlantic	41	1674	(— • —)	0.086	(0.026, 0.189)
South/Central	44	1143	(0.030	(0.012, 0.050)
Moutain/Southwest	45	1252	(• • · · · · · · · · · · · · · · · · ·	0.045	(0.013, 0.095)
West/Pacific	36	1368	(→)	0.019	(0.002, 0.038)
Age					
18-44	140	3349	(↓ ● →)	0.059	(0.028, 0.099)
45-69	118	3436	(•• †)	0.034	(0.017, 0.050)
70+	46	1273	(<u> </u>	0.035	(0.009, 0.074)
Sex					
Female	182	4241	(+●)	0.055	(0.028, 0.090)
Male	122	3817	()	0.035	(0.015, 0.058)
Race					
American Indian/Alaska Native	5	98	(<u> </u>	0.068	(0.007, 0.209)
Asian Only	15	499	$(-\bullet)$	0.020	(0.003, 0.037)
Black Only	46	761	; (0.142	(0.056, 0.274)
Pacific Islander Only	2	12*			
White Only	209	6243	(••) i	0.031	(0.015, 0.044)
Multiple Races	13	290	$(-\bullet+)$	0.025	(0.003, 0.059)
Others	14	155	(<u> </u>	0.111	(0.042, 0.219)
Ethnicity			1		
Non-Hispanic	239	6777	(0.043	(0.022, 0.064)
Hispanic	65	1281	(0.061	(0.024, 0.115)
Urban/Rural					
(mostly) Rural	23	1135	(●)	0.011	(0.000, 0.025)
Urban	281	6923	(→● →)	0.053	(0.032, 0.077)
			0 0.05 0.1 0.15 0.2 0.25 0.3		
			Estimated prevalence		

Figure 3: Undiagnosed seroprevalence in main demographic categories. Six main categories utilized during quota-based sampling: region, age, sex, race, ethnicity, and urban/rural. Seropositivity estimates of samples that had a full clinical questionnaire completed and successful sampling. Data are weighted estimates \pm 95% confidence intervals. Dashed line = weighted national seroprevalence estimate. * = n value too low to make proper weighted estimate, raw positivity displayed.

	Pos No.	Total No.	_	Estimate	95% CI
Overall	304	8058	(0.046	(0.026, 0.065)
Direct contact with patients	250	6700		0.045	(0.025.0.067)
Yes Work site	54	1358	\leftarrow	0.045	(0.016, 0.094)
At home only At home or at work	116 25	3089 701		0.030	(0.015, 0.041) (0.010, 0.061)
At work only Not currently working	73	1858		0.056	(0.023, 0.102) (0.021, 0.104)
Other Have children <18yr live in the household	4	151	(• · · · · · · · · · · · · · · · · · ·	0.016	(0.000, 0.049)
No Yes	204 100	5442 2616	$(- \bullet) $	0.044 0.049	(0.021, 0.070) (0.022, 0.083)
Education level <= High school	7	210	(<u> </u>	0.055	(0.015, 0.122)
Some college or technical school	260 37	1113		0.041	(0.020, 0.066)
Other Own	18 208	375 6058	← → ●	-) 0.105 0.041	(0.007, 0.357) (0.022, 0.059)
Rent Employment status	78	1625	\leftarrow	0.043	(0.019, 0.073)
Employed Other	228 54	5738 1920		0.040 0.025	(0.021, 0.059) (0.007, 0.046)
Unemployed Have health care coverage	22	400	(0.139	(0.040, 0.309)
No Yes Had flu shat	293	7851	\leftarrow	0.047	(0.025, 0.066)
No Ves	114 189	2963 5091		0.055	(0.028, 0.088) (0.016, 0.043)
Had Pheunomia vaccine Don't know	28	686		0.034	(0.009, 0.072)
No Yes	183 93	4596 2776	(\rightarrow)	0.057 0.023	(0.031, 0.086) (0.008, 0.034)
Had BCG vaccine Don't know	77	2035	(0.051	(0.015, 0.110)
No Yes Had a beart attack	116	2836	(0.040	(0.020, 0.080)
No Yes	301 3	7943 111		0.046	(0.026, 0.066) (0.000, 0.097)
Had angina or coronary heart disease No	301	7815	(—• —)	0.047	(0.027, 0.067)
Yes Had a stroke	3	236		0.017	(0.000, 0.054)
Yes Had asthma	1	78	↔	0.048	(0.000, 0.015)
No Yes	263 41	6634 1418		0.049	(0.028, 0.071) (0.007, 0.057)
Still have asthma No	15	489	(●)	0.015	(0.000, 0.030)
Yes Had skin cancer	23	7208		0.043	(0.009, 0.102)
Yes Had any other types of cancer	31	824	(\bullet)	0.030	(0.011, 0.050)
No Yes	274 28	7490 562	$\xleftarrow{\bullet}$	0.044 0.058	(0.024, 0.065) (0.022, 0.113)
No	298	7879		0.047	(0.027, 0.067)
Have some form of arthritis	250	6527		0.019	(0.029, 0.078)
Yes Have a depressive disorder	54	1524	(- -)	0.026	(0.009, 0.042)
No Yes	244 57	6489 1489		0.048	(0.027, 0.072) (0.013, 0.052)
No	299	7872	((· · ·)))))))) (· · · · · ·	0.045	(0.026, 0.065)
Have diabetes No	293	7614	(, , , , , , , , , , , , , , , , , , ,	0.049	(0.029, 0.071)
Yes Have HIV or weakened immune system	11	444	(●)	0.008	(0.000, 0.015)
No Yes Had a known COVID19 exposure	291 10	166	(└● ;) (└ ●))	0.038	(0.022, 0.053) (0.014, 0.226)
No Yes	133 99	5960 616	() ()	0.027	(0.008, 0.050) (0.084, 0.255)
Sick since 01Jan2020 No	88	4104	(\rightarrow)	0.044	(0.017, 0.081)
Yes Traveled outside of the US since Oct 2019	210	3794		0.048	(0.029, 0.067)
Yes	209 95	1836	$\overbrace{\longleftarrow}^{\bullet}$	0.061	(0.021, 0.005) (0.029, 0.104)
			0 0.05 0.1 0.15 0.2 0.25 0.3		
			Estimated prevalence		

Figure 4: Seroprevalence estimates of health and behavioral traits. Seropositivity estimates of samples

341 that had a full clinical questionnaire completed and successful sampling. Data are weighted estimates \pm

342 95% confidence intervals. Dashed line = weighted national seroprevalence estimate.

343		REFERENCES
344		
345	1.	Fauci AS, Lane HC, Redfield RR. Covid-19-navigating the uncharted. In: Mass Medical Soc;
346		2020.
347	2.	Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol Mech
348		Dis. 2008;3:499-522.
349	3.	Taubenberger JK, Morens DM, 1918 Influenza: the mother of all pandemics, <i>Revista Biomedica</i> ,
350	-	2006:17(1):69-79.
351	4.	Huang AT, Garcia-Carreras B, Hitchings MD, et al. A systematic review of antibody mediated
352		immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody
353		responses with severity of disease <i>medRxiv</i> 2020.
354	5	Long O-X, Liu B-Z, Deng H-L et al. Antibody responses to SARS-CoV-2 in patients with COVID-
355	5.	19 Nature medicine 2020.1-4
356	6	Ainsworth M Andersson M Auckland K et al Performance characteristics of five immunoassays
357	0.	for SARS-CoV-2: a head-to-head henchmark comparison The Lancet Infectious Diseases 2020
358	7	Klumpn-Thomas C Kalish H Drew M et al Standardization of enzyme-linked immunosorbent
350	7.	assays for serosurveys of the SARS CoV 2 pandemic using clinical and at home blood sampling
360		<i>assays</i> for scrosurveys of the SARS-Cov-2 pandenne using ennical and at-nonic blood sampling.
361	8	Stadlhauer D. Amanat F. Chromikova V. et al. SARS CoV 2 Seroconversion in Humans: A
362	0.	Detailed Protocol for a Serological Assay Antigen Production and Test Setup Current Protocols
363		in Microbiology 2020:57(1):e100
364	9	Dan IM Mateus I Kato V et al Immunological memory to SARS-CoV-2 assessed for greater
365).	than six months after infection <i>bioPriv</i> 2020
366	10	Chi X. Van R. Zhang I. et al. A neutralizing human antibody hinds to the N terminal domain of the
367	10.	Spike protein of SADS CoV 2 Science 2020:260(6504):650 655
368	11	He V Thou V Liu S et al. Recenter binding domain of SARS CoV spike protein induces highly
360	11.	notent neutralizing antibodies; implication for developing subunit vaccine. <i>Biochemical and</i>
370		biophysical research communications 2004:224(2):773-781
370	12	Liu I. Wang P. Nair MS, et al. Potent neutralizing antibodies against multiple epitones on SARS
371	12.	CoV 2 spike Nature 2020:584(7821):450 456
372	12	Dinto D. Dark VI. Beltramello M. et al. Cross neutralization of SADS CoV 2 by a human
373	13.	monoclonal SADS CoV antibody Nature 2020:1.6
375	14	Shi P. Shan C. Duan V. at al. A human neutralizing antibody targets the recentor hinding site of
375	14.	SADS CoV 2 Nature 2020:1.8
370	15	Wang 7 Lorenzi IC Musclesch E et al Enhanced SADS CoV 2 Neutralization by Secretary IgA
278	13.	in vitro hie Prin 2020
370	16	Hicks I Klumm Thomas C Kalish H at al Saralagia gross reactivity of SADS CoV 2 with
373	10.	andemia and apagened Detectorenequiruses, madDrin, 2020
381	17	Especite D. Mehalko I. Drew M. et al. Optimizing high yield production of SADS CoV 2 soluble.
282	17.	esposito D, Menaiko J, Diew M, et al. Optimizing ingli-yield production of SAKS-Cov-2 soluble spike trimore for sorology oscowe. <i>Protein Expression and Dwiffection</i> , 2020;105686
202	10	Spike uniters for service stays. From Expression and Fullication. 2020.105060.
202	10.	demain (DDD) for apple of a service production of SARS-Cov-2 spike receptor-binding
204	10	Contain (RBD) for serology assays. Protein expression and purification. 2020;105802.
286	19.	System System Systematics and Data In U.S. Denostment of Health and Hymen Services
200		System Survey Questionnaire and Data. In: U.S. Department of Health and Human Services
201	20	CIDCaP, ed2020.
200	20.	The Langet infectious diagrage 2020,20(5),522,524
200	21	Ine Luncei injectious diseases. 2020;20(3):353-354. Mahra MD, Dagai SS, Kuyi S, Hanny TD, Datal AN, Candiavagaylan Diagaga, Dura Thereney, and
201	21.	Mortality in Covid 10 New England Journal of Madicine 2020;222(25):=102
307	22	Protanty in Covid-19. New England Journal of Medicine. 2020;382(23):e102.
302	<i>LL</i> .	Rustamatic review and meta analysis Clin Microbiol Infact 2020
575		systematic review and meta-analysis. Cini whet oblot inject. 2020.

- Caini S, Bellerba F, Corso F, et al. Meta-analysis of diagnostic performance of serological tests for
 SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. *Euro Surveill*.
 2020;25(23).
- 397 24. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody Tests in Detecting
 398 SARS-CoV-2 Infection: A Meta-Analysis. *Diagnostics (Basel)*. 2020;10(5).
- 25. Lee CY, Lin RTP, Renia L, Ng LFP. Serological Approaches for COVID-19: Epidemiologic
 400 Perspective on Surveillance and Control. *Front Immunol.* 2020;11:879.
- 40126.Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-40219: systematic review and meta-analysis. *BMJ*. 2020;370:m2516.
- 403 27. Biggs HM, Harris JB, Breakwell L, et al. Estimated community seroprevalence of SARS-CoV-2
 404 antibodies—two Georgia counties, April 28–May 3, 2020. *Morbidity and Mortality Weekly Report.*405 2020;69(29):965.
- 40628.Bryan A, Pepper G, Wener MH, et al. Performance characteristics of the Abbott Architect SARS-407CoV-2 IgG assay and seroprevalence in Boise, Idaho. Journal of clinical microbiology. 2020.
- 408 29. Dietrich ML, Norton EB, Elliott D, et al. SARS-CoV-2 Seroprevalence Rates of Children in Louisiana During the State Stay at Home Order. *medRxiv*. 2020.
- 410 30. Feehan AK, Fort D, Garcia-Diaz J, et al. Seroprevalence of SARS-CoV-2 and infection fatality
 411 ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020. *Emerging infectious diseases*.
 412 2020;26(11):2765.
- 413 31. Havers FP, Reed C, Lim T, et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the
 414 United States, March 23-May 12, 2020. *JAMA*. 2020;180(12):1576-1586.
- 415 32. McLaughlin CC, Doll MK, Morrison KT, et al. High community SARS-CoV-2 antibody
 416 seroprevalence in a ski resort community, Blaine County, Idaho, US. preliminary results. *Medrxiv*.
 417 2020.
- 418 33. Menachemi N, Yiannoutsos CT, Dixon BE, et al. Population point prevalence of SARS-CoV-2
 419 infection based on a statewide random sample—Indiana, April 25–29, 2020. Morbidity and
 420 Mortality Weekly Report. 2020;69(29):960.
- 421 34. Ng DL, Goldgof GM, Shy BR, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. *Nature communications*. 2020;11(1):1-7.
- 423 35. Rosenberg ES, Tesoriero JM, Rosenthal EM, et al. Cumulative incidence and diagnosis of SARS424 CoV-2 infection in New York. *medRxiv*. 2020.
- 36. Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2–Specific Antibodies Among
 Adults in Los Angeles County, California, on April 10-11, 2020. Jama. 2020.
- 37. Sutton M, Cieslak P, Linder M. Notes from the Field: Seroprevalence Estimates of SARS-CoV-2
 Infection in Convenience Sample—Oregon, May 11–June 15, 2020. Morbidity and Mortality
 Weekly Report. 2020;69(32):1100.
- 43038.Elliott MR, Valliant R. Inference for nonprobability samples. Statistical Science. 2017;32(2):249-431264.
- 432 39. Hill D. The dirty little secret pollsters need to own up to. *The Washington Post.* 2020.